Recently, ForSight Robotics Ltd. appointed Sharon Levita as Chief Financial Officer. She is responsible for leading the company’s strategic and financial operations, focusing on driving business strategy, expanding strategic partnerships, and managing financial and growth objectives. This personnel appointment was announced two months ago.
"Sharon is a proven leader dedicated to driving healthcare innovation," said Dr. Joseph Nathan, Co-Founder and Chief Medical Officer of ForSight Robotics. "Her expertise in global medtech companies and extensive management experience, from formulating successful go-to-market strategies to expanding global partnerships, are unparalleled and align with the company’s vision. As we continue advancing the development of the ORYOM surgical robotic platform, we are thrilled to welcome Sharon to our team."
Before joining, he served as a senior executive in Medtronic's "Cranial and Spinal" business.
Levita has over 20 years of experience in the medical technology industry. She most recently served as the Head of Business Development and Strategy for Medtronic's Cranial and Spinal Technologies division. Prior to that, she was Vice President of Israel Operations and Medtronic Site Leader (formerly Mazor Robotics, a robotic spine surgery company). Before this role, Levita spent over a decade at Mazor Robotics as Chief Financial Officer and Vice President of Business Operations, leading the company’s $1.6 billion acquisition by Medtronic in 2018. Her earlier career includes various leadership positions at Lumenis, a medical laser company, and KPMG Hungary.
"Joining ForSight Robotics is an exciting moment," said Levita. "The company has tremendous potential to help millions of patients worldwide. I value its mission to democratize access to high-quality ophthalmic surgical care and am eager to collaborate with the team to strengthen the company's forward momentum and collectively make a global impact."
Gathering a豪华 team and numerous明星 capitals
For millions of people around the world, poor vision and limited access to high-quality ophthalmic surgical care are common issues. Currently, there are many problems in ophthalmic surgery: limitations in human accuracy, an insufficient number of specialized doctors, and the need for years of clinical experience to achieve surgical precision. Therefore, ophthalmic surgical robots seem poised to become a standard feature in the future.
ForSightTeamForSight Robotics is an Israeli ophthalmic surgical robotics company established in 2020, dedicated to advancing ophthalmic surgery through robotics, advanced visualization, and data analysis. The company’s platform will integrate stereoscopic imaging technology for surgical planning, real-time image guidance, and visualization to ensure continuous improvement in surgical techniques and achieve precision movements of just a few microns, surpassing human surgical capabilities.In March 2021, ForSight Robotics raised $10 million in a seed funding round from Eclipse Ventures and Mithril Capital. Notably, the founding team of ForSight Robotics includes Fred Moll (founder of Intuitive Surgical) and Moshe Shoham (founder of Mazor).In the past year, ForSight Robotics raised a record-breaking $55 million in Series A funding to increase the accessibility of ophthalmic surgeries worldwide. The round was led by Adani Group, with existing investors Eclipse Ventures and Mithril Capital co-leading. Many new investors joined, including Provenio Capital, Precision Capital, Reiya Ventures, and the Ljungstrom family office. Other prominent private investors also participated in this round.After financing, the company doubled in size to 50 employees and appointed Dr. Yaron Levinson as the head of product and Ran Mendelewicz as the head of robotics, expanding its leadership team. Levinson joined the company after a decade in the surgical robotics industry, most recently serving as VP of R&D at Momentis Surgical, where he supported the regulatory process to obtain FDA approval for the company's robotic system. Mendelewicz joined ForSight Robotics after 20 years in the medical device industry, most recently serving as VP of R&D at intraocular implant company Nano Retina.The World's FirstCataracts and Wide-rangingApplied toRobotic Surgery Platform for Eye Diseases
Its ORYOM ("Light" in Hebrew) system is the world's first robotic surgery platform for treating cataracts and a wide range of eye diseases, utilizing AI-based algorithms, advanced computer vision, and micro-mechanical operation. ForSight Robotics stated that Sharon Levita’s successful experience in global TOP enterprises will help the company drive medical innovation.The ORYOM platform is capable of performing therapeutic and preventive ophthalmic surgeries, such as: cataracts, glaucoma, and retinal diseases. The ORYOM platform leverages high-precision robotics, advanced visualization, and cognitive data analysis – giving it unprecedented advantages.ORYOM™ Surgical Platform Offers Extreme Dexterity and Operability, Featuring a Miniature 14-DOF Microsurgical Robot Capable of Performing Delicate Tasks. Hybrid Motion Architecture Allows Access to Any Area Within the Human Eye.2. ORYOM™ Advanced VisualizationAdvanced stereoscopic imaging technology for surgical planning, real-time image guidance, and unparalleled visualization3. Advanced Data AnalysisThe most advanced computational methods use machine learning to continuously evolve and refine surgical techniques.Many of the leading causes of blindness worldwide can be prevented through timely surgical intervention. Ophthalmic microsurgery is a complex and challenging discipline that requires years of practical experience, and there is currently a shortage of well-trained ophthalmic surgeons globally to meet this demand.The ophthalmic surgical robotics market is "still largely untapped" as robotics currently represent only a small portion of the overall surgical market. At present, approximately 5% of surgeries are performed robotically, with about 95% conducted manually by humans. The establishment of robotic surgery platforms will enable the scaling of ophthalmic procedures while addressing preventable blindness on a global scale.ForSight Aims to Bridge the Global Gap in Access to Eye Surgery and Help Over 1 Billion People with Preventable Vision Impairment and Eye Diseases. ForSight's first procedure is cataract surgery, the most common surgery with approximately 28 million procedures performed worldwide each year. According to the National Institutes of Health, more than 25 million Americans have cataracts, and there are hundreds of millions of people with cataracts worldwide."We have developed a robotic platform capable of performing ophthalmic surgeries, which are currently conducted manually with the assistance of microscopes. A successful cataract surgery demands significant time, exceptional skill, and years of experience," said Nathan. "Robots are ten times more precise than humans. We are currently working on a fully autonomous robot that will address the global shortage of ophthalmologists. We already have a system successfully tested on animals, and we estimate that, at the latest by 2026, our robot will be ready to treat humans."｜Source: Medical Device Innovation Network, ReferenceForSight Official Website, MedRobot, etc.
Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please evaluate carefully. If it involves the content, copyright, or other issues of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the content of the article itself. The Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.
P/R/E/V/I/E/W
